Elly Gerald Stoica

Array ( [id] => 15527257 [patent_doc_number] => 20200055934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => THERAPEUTIC AGENTS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/541107 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290807 [patent_doc_number] => 20190388539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/535610 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175497 [patent_doc_number] => 20190358340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/535191 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16535191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15180871 [patent_doc_number] => 20190361027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => METHODS FOR DETERMINING BREAST CANCER RISK [patent_app_type] => utility [patent_app_number] => 16/528052 [patent_app_country] => US [patent_app_date] => 2019-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16528052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126224 [patent_doc_number] => 20210300992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => Soluble Polypeptides and Methods of Using Same for Inhibiting Leukemia Inhibitory Factor Activity [patent_app_type] => utility [patent_app_number] => 17/260473 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15321137 [patent_doc_number] => 20200000898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => CONDITIONAL SUPERAGONIST CTL LIGANDS FOR THE PROMOTION OF TUMOR-SPECIFIC CTL RESPONSES [patent_app_type] => utility [patent_app_number] => 16/450302 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913980 [patent_doc_number] => 20210187072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA [patent_app_type] => utility [patent_app_number] => 17/050414 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878263 [patent_doc_number] => 11028399 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => CTLA4/PD1 targeted/immunomodulatory fusion proteins [patent_app_type] => utility [patent_app_number] => 16/443973 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 13163 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258870 [patent_doc_number] => 20210371855 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHODS OF INHIBITING PROLIFERATIVE CELLS [patent_app_type] => utility [patent_app_number] => 17/252430 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -138 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435421 [patent_doc_number] => 20200031894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 16/443226 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866275 [patent_doc_number] => 20200140541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => ANTIBODIES THAT BIND CELL SURFACE GRP78 AND THEIR USE FOR DETECTION OF CANCER [patent_app_type] => utility [patent_app_number] => 16/438289 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703051 [patent_doc_number] => 10952964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Targeted delivery of drugs to the myometrium via polypeptides that bind to the oxytocin receptor [patent_app_type] => utility [patent_app_number] => 16/435061 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 7003 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16114433 [patent_doc_number] => 20200209239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR [patent_app_type] => utility [patent_app_number] => 16/433992 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19594234 [patent_doc_number] => 12152064 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => BTNL3/8 targeting constructs for delivery of payloads [patent_app_type] => utility [patent_app_number] => 16/972534 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 25 [patent_no_of_words] => 14121 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14990997 [patent_doc_number] => 20190314456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 16/429635 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16429635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16548600 [patent_doc_number] => 10881739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Interleukin-11 PEGylation reaction intermediate composition [patent_app_type] => utility [patent_app_number] => 16/418841 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 9229 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695534 [patent_doc_number] => 10946103 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Methods of treatment using a branched amino terminal pegylated Il-11 composition [patent_app_type] => utility [patent_app_number] => 16/418850 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 9218 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209773 [patent_doc_number] => 20190367573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => p53-BH3 Hybrids for Cancer Gene Therapy [patent_app_type] => utility [patent_app_number] => 16/414683 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209773 [patent_doc_number] => 20190367573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => p53-BH3 Hybrids for Cancer Gene Therapy [patent_app_type] => utility [patent_app_number] => 16/414683 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209773 [patent_doc_number] => 20190367573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => p53-BH3 Hybrids for Cancer Gene Therapy [patent_app_type] => utility [patent_app_number] => 16/414683 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414683 [rel_patent_id] =>[rel_patent_doc_number] =>)